for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amyris Inc

AMRS.OQ

Latest Trade

3.24USD

Change

-0.16(-4.71%)

Volume

354,703

Today's Range

3.21

 - 

3.50

52 Week Range

1.87

 - 

6.05

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.40
Open
3.48
Volume
354,703
3M AVG Volume
18.27
Today's High
3.50
Today's Low
3.21
52 Week High
6.05
52 Week Low
1.87
Shares Out (MIL)
103.40
Market Cap (MIL)
358.71
Forward P/E
-1.48
Dividend (Yield %)
--

Next Event

Q4 2019 Amyris Inc Earnings Release

Latest Developments

More

Temasek Holdings Dissolves Share Stake In Tradeweb Markets, SVMK and Amyris

Amyris Files Prospectus Relating To Potential Offer Of Up To 103.6 Mln Shares Of Common Stock By Selling Stockholders

Amyris Executes Agreements To Resolve CVI Heights Debt

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amyris Inc

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. The Company is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including performance chemicals, solvents, lubricants, flavors and fragrances (F&F), cosmetics ingredients, pharmaceuticals, and nutraceuticals. The Company intends to apply its technology to the development of pharmaceutical products. The Company applies its bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products.

Industry

Chemical Manufacturing

Contact Info

5885 Hollis St Ste 100

+1.510.4500761

https://www.amyris.com/

Executive Leadership

Geoffrey M. Duyk

Independent Interim Chairman of the Board

John G. Melo

President, Chief Executive Officer, Director

Jonathan R. Wolter

Interim Chief Financial Officer

Eduardo Alvarez

Chief Operating Officer

Nicole Kelsey

General Counsel, Secretary

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.2K
EPS (USD)

2016

-5.550

2017

-3.050

2018

-3.440

2019(E)

-2.300
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.13
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-188.08

Latest News

Latest News

BRIEF-Amyris Inc Files For Non-Timely 10-K With U.S. SEC

* AMYRIS INC FILES FOR NON-TIMELY 10-K WITH U.S. SEC Source text: (https://bit.ly/2H66fh4) Further company coverage:

BRIEF-Amyris Reports Q4 Gaap Loss Per Share $0.17

* AMYRIS REPORTS ANOTHER STRONG QUARTER WITH SOLID OPERATING PERFORMANCE AND 2017 REVENUE OF $143.4 MILLION UP 113% OVER 2016

BRIEF-DSM acquires Brazilian production facility from Amyris

* DSM expands strategic alliance with Amyris and acquires Brazilian production facility from Amyris

BRIEF-Amyris posts Q3 GAAP loss of $1.14 per share

* Amyris reports another strong quarter of product sales growth and expects strong finish for 2017

BRIEF-Amyris files for offering of up to 26.2 mln shares of common stock by selling stockholders

* Amyris Inc files for offering of up to 26.2 million shares of common stock by the selling stockholders - SEC filing Source text: (http://bit.ly/2zaU4Od) Further company coverage:

BRIEF-Amyris Inc enters into agreement with Koninklijke DSM N.V.

* Amyris enters into product development and production agreement with Royal DSM for human nutrition ingredient

BRIEF-Amyris enters into second major product development with Royal DSM

* Amyris Inc enters into second major product development and production agreement with Royal DSM

BRIEF-Amyris Q2 loss per share $0.46

* Amyris delivers another strong quarter with revenue of $25.7 million and product sales increase of 159% over 2nd quarter of 2016

BRIEF-Vivo Capital VIII reports 9.9 pct stake in Amyris

* Vivo Capital VIII LLC reports 9.9 percent passive stake in Amyris Inc as of August 2, 2017 - SEC filing Source text: (http://bit.ly/2vCkff7) Further company coverage:

BRIEF-Amyris files for offer and sale of up to 42.27 mln shares

* Amyris Inc files for offer and sale of up to 42.27 million shares of co's common stock by the selling stockholders - sec filing Source text: (http://bit.ly/2hwaLw0) Further company coverage:

BRIEF-Amyris says second tranche of $50 mln in a private placement days is being led by a $25-mln investment from Koninklijke​

* Amyris announces agreements for $50 million in second tranche of equity financing, exceeding previous target of $95 million

BRIEF-Amyris enters into first product development, production agreement with Royal DSM

* Amyris enters into first product development and production agreement with Royal DSM for food and nutrition molecule

BRIEF-Amyris, on June 30, 2017, company issued, sold an amended, restated note in principal amount of $3 mln to purchaser

* Amyris Inc - on June 30, 2017, company issued and sold an amended and restated note in principal amount of $3.0 million to purchaser - sec filing

BRIEF-Amyris and government of Queensland announced plans to develop a industrial biotechnology hub in Southeast Asia

* Amyris Inc and government of Queensland, Australia announced plans to develop a industrial biotechnology hub in Southeast Asia Source text for Eikon: Further company coverage:

BRIEF-Amyris announces reverse stock split

* Amyris announces reverse stock split - delivering on strong product revenue growth and execution

BRIEF-Amyris reports Q1 loss per share of $0.13

* Amyris reports 164 pct product revenue growth over prior year & continued strong outlook

BRIEF-Amyris on-track to double revenue for vitamin e partnership

* Amyris on-track to double revenue for vitamin e partnership with nenter & announces exclusive vitamin a license with royal DSM

BRIEF-Royal DSM to make equity investment in Amyris

* Royal DSM to make equity investment in amyris with the purpose of establishing a long-term relationship Source text for Eikon: Further company coverage:

BRIEF-Royal DSM to make equity investment in Amyris

* Royal DSM to make equity investment in Amyris with the purpose of establishing a long-term relationship Source text for Eikon: Further company coverage:

BRIEF-Amyris announces agreements for up to $95 mln in equity financing

* Amyris announces agreements for up to $95 million in equity financing and in-process initiative to significantly reduce debt

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up